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ABSTRACT OF THESIS 
 
PROCESS OPTIMIZATION AND VALIDATION OF AN ASSAY 
FOR HIGH-THROUGHPUT SCREENING 
 
A biological assay is designed to set up a rapid and robust drug-screening system on a 
small scale. An assay is considered as a single unit of a platform to screen various 
compounds for aiding in drug discovery. Each assay is carried out in a 96-well plate, each 
of whose wells consists of the biological component called the Spheroids. The value of 
each assay lies in it facilitating for versatile screening applications. The spheroid is 
considered as a micro-structural product. And the addition of various compounds for 
testing is performed in each well (consisting of the spheroids). The focus has been to put 
forth the production principles and validation strategies to run the biological assay and 
test its efficacy to be used for screening in high volumes. The assay development 
illustrates processing and validation techniques. The goal is to develop optimized 
standards to process the assay, addressing various quality control issues, from the raw 
material to the end-product stage. Such an approach also brings interesting analogies of 
biological process in a manufacturing scenario. The developed system incorporates a 
value stream approach, by pulling the product from the customer end.  
The process involves simply encapsulating HUVECs (Human Umbelical Vein 
Endothelial cells) from the raw material stage, culturing to form the spheroid and 
transferring the component to assemblage in a 96-well format undergoing stages of heat 
treatments. The small scale screening system allows the use of small amounts of drug, 
which is especially essential for new drug synthesis or in rapid decision making to find 
out any unknown potent compounds. The design of optimal processes in product 
development of the spheroid assay is illustrated. Thus in light of the value of this assay, 
developing the production system has been pivotal so as to produce quality spheroids in 
the 96-well plate formats. The quantification of the stimulatory and inhibitory effects of 
the different agents is required to help understand the complex biological behavior 
involved. The goal is to validate the data using image analysis software. The image 
analysis helps determine the quantification to be accurate, objective, and consistent. The 
quality of the product is tested by the reproducibility and robustness of the assay.  
Keywords: Optimization, Validation, Variability, FMEA, Angiogenesis, Assay, 
Spheroids, In vitro, High-throughput  
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 CHAPTER I INTRODUCTION 
1.1 Motivation 
Drug screening business for identifying potential drugs has hit the market picture since a 
decade. There are many manufacturing models used for drug screening purposes which 
draw parallels in a manufacturing scenario. In a recent release this year, the Food and 
Drug Administration announced it would identify ways of modernizing the drug 
development process under its so-called "critical path" initiative to take a drug from 
laboratory to patient. With more than 90 % of drugs failing when tested in humans, 
scientifically engineered tools are considered to improve the way the drugs are tested [1]. 
Given the current scenario with the dramatic failure rate of drug screening in 
pharmaceutical companies, the government is taking efforts to develop assays to benefit 
the drug screening platform in the public sectors. 
Drug screening comprises of generating an artificial scenario of a desired human 
functioning system. Thus developing this artificial scenario for a prototype model is the 
main manufacturing goal of this project. The basic processing of this system includes 
mimicking of the blood vessels formation using a generated biological component and 
then the drug treatment is added. The formation of the biological component to desired 
geometric shape is also attained in the process. Various models were experimented and 
analyzed for this purpose and an optimal model was implemented. The concepts of 
problem solving, production planning, inspection, statistical process control, variability 
assessment, data validation are used in the manufacturing process. This thesis brings into 
light a unique way of describing a biological process. Since the process involves 
assemblage of two major components it brings scope to depict it in a manufacturing 
scenario. There has been in depth analysis of statistical process control in this thesis, 
which in a manufacturing system works toward continuous improvement or in generating 
areas for continual improvement. The basic concept of studying variation and using 
statistical signals to improve performance can be applied to any area. Such areas can be 
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on the shop floor, a research laboratory or in the office. Some examples I would quote in 
support of the statement would be machines or equipment and product (performance 
characteristics), processes, bookkeeping (deviation and error rates), waste analysis (scrap 
rates), etc.  
Historically, statistical process methods have been routinely applied to parts, rather than 
processes. Application of SPC to control output (such as the end product) of the system 
should be only the first step. The industrial revolution has taught us that until the 
processes that generate the output become the focus of our efforts, the full power of these 
methods to improve quality, increase productivity and to reduce cost may not be fully 
realized. To bring some traditional highlights into manufacturing, it often depended on 
production to make product and on quality control to inspect the final product and screen 
out items not meeting specifications. Work is often checked and rechecked to catch 
errors. Both cases involve a strategy of detection, which is wasteful, because it allows 
time and resources to be invested. It is much more effective to avoid waste by not 
producing the unusable output in the first place, which is a strategy of prevention. Thus 
the research laboratory adopts ways of identifying and preventing the error before 
occurrence through intense study, problem solving and balancing variability. The 
statistical process control and its validation are elucidated in chapter four and thus draw 
parallels of defining the manufacturing processes in biology. 
Biologically speaking, the goal is to develop a toolbox to help better understand the inter-
connected networks of molecules that comprise cells, their interactions, regulation, and 
the combination of molecular bonding that lead to disease. These events are studied 
herein specific to angiogenesis, which is the development of new blood vessels that 
branch out from existing vessel formations. This further relates back to the objective of 
producing an assay which incorporates the above mentioned events to the fulfillment of 
successfully screening and validating various drug compounds. And this process of 
systematically screening tens to thousands of compounds is known to be High 
Throughput screening (HTS) [2]. The complex high-content screening (HCS) information 
coupled with HTS has the incredible power of capturing every shape of biology to allow 
grounds for decision making in drug discovery based on prioritization. This dual HCS-
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HTS system brings immense value to drug screening aiding in time saving, cost reduction 
and in capturing intellectual protection. 
 
Considering such a need, the current thesis addresses one such path to develop a platform 
for high throughput screening of drugs. This involves high level design in consideration 
of the right testing model to give reproducible and validating results. There are various 
genetic, tumor and surgical models applicable to help in developing drug discovery. But 
the void being reported is the pace in drug discovery, a critical research within the 
laboratory has gone into defining and producing the right cell-based assay for the high 
throughput screening system. With the identification of the right assay for mimicking 
blood vessel formation, the development of the assay and image analysis using 
proprietary software for validating the assay results is illustrated herein.  The image 
analysis gives scope to generating library of data containing various pattern behavior of 
spheroids under varied conditions (such as growth factors or drug compounds based on 
the hypothesis for the experiment) and extracting biologically relevant information by 
comparisons made with drug candidates of unknown mechanisms. Such an assay helps 
gain an understanding of the nature of chemical space and how it provides a structure for 
organizing and analyzing biological/pharmacological data. In addition, the scientists will 
gain a very basic understanding of how multi-criterion decision making can be applied to 
help prioritize compounds as potential drug candidates. This inter-disciplinary approach 
elucidates the roadmap for angiogenesis drug discovery platform. The tools developed in 
the research are important as they establish relation between biology and engineering 
disciplines. 
 
Any product that is new and before it hits the market undergoes intense research and 
development. Be it a car or a biological product, a prototype model is developed, 
processed and validated for its performance. When such validation becomes high in 
numbers, technology comes into picture. Thus the high throughput systems make use of 
technology to address processing and validation of a product. 
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The high throughput systems are used to ensure the product’s reproducibility and there 
lays the true value to keep up to the ever growing demand. Unlike the car manufacturing 
which falls in a macroscopic work structure, the product in this study has a microscopic 
work flow and is visible only under a microscope. This microscopic work flow is 
considered in drug screening because it saves time and money spent on testing animal 
models. Like the way all cars are checked for consistency in performance, the product in 
each of the wells during its validation stage needs to be assessed for its consistent 
performance. 
 
 
 
N x 
N x  
CAR MANUFACTURING 
Reproducibility 
Macroscopic work flow 
Consistency in performance 
DRUG SCREENING 
Figure 1: Illustration of high throughput systems 
 
Each well of the 96-well plate is considered a product. This well will face the decision of 
the drug stating if it is potential or not. Thus the value lies in making it reproducible. The 
goal of the study was to develop the microscopic product, make it reproducible and 
validate its performance. We will see further where the product applies and its functions.  
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1.2 Angiogenesis and the Definition of Need 
Angiogenesis is the formation of new blood vessels from pre-existing vessels. 
Angiogenesis is a normal physiological process that occurs in growth and development, 
as well as in wound healing. However, this is also a fundamental step in the transition of 
tumors from a dormant state to a malignant state and under excessive angiogenesis it is 
observed as abnormal rapid proliferation of blood vessels, which is implicated in many 
diseases, including arthritis, psoriasis and age-related macular degeneration [3].  
When tissues need more oxygen, for example, they release molecules that encourage 
blood vessels to grow. The ability to inhibit angiogenesis and turn off the blood supply to 
tumors could potentially lead to a new generation of cancer therapies.
 
ANGIOGENESIS 
PHYSIOLOGICAL 
ANGIOGENESIS 
PATHOLOGICAL 
ANGIOGENESIS 
EXCESS INSUFFICIENT 
HEALING GROWTH & 
DEVELOPMENT 
 
BLINDNESS RHEUMATOID 
ARTHRITIS 
CANCER PSORIASIS   AIDS 
COMPLICATION 
STROKE HEART 
DISEASE 
ULCERS SCHERODERMA INFERTILITY 
Figure 2: Angiogenesis schematic  
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Sprouting Angiogenesis Sprouting angiogenesis a cascade of morphological (structural 
organization) events as explained below is a common form of blood vessel growth. The 
Endothelial Cell (EC) is commonly known for inducing sprouts in-vitro*, indicating in 
vivo*-like tube formation. ECs line the entire circulatory system, from the heart to the 
smallest capillary [3]. In vivo, ECs form a monolayer of cells at the innermost surface of 
the blood vessels that attach onto an underlying basement membrane (a supporting 
structure that acts as vessel walls) forming an interface between circulating blood and the 
vessel wells.  
 
 
 
 
 
 
 
 
 
 
 
 
* in-vitro: An experimental technique performed outside of a living organism or cell [3] 
* in-vivo: A condition existing in a living organism or an experiment performed on a whole/living organism 
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The key events of angiogenesis, also called the angiogenic cascade, involve: 
o The initial activation of the endothelial cells to escape from the vessel walls.  
o Gradual migration from 2D monolayer to 3D macromolecular space into the 
surrounding matrix to form solid sprouts connecting neighboring vessels.  
o With gradual cell migration and proliferation, these sprouts then become full-
fledged vessel networks to slowly form new blood vessels and move in towards 
the angiogenesis stimulus (the tumor/damage site)[4, 5].  
 
Figure 3: Angiogenesis pathway in-vivo (Reference: AMP lab GmbH 
http://www.amplab.de/angiogenesis.htm) 
Given the potent therapeutic uses of angiogenic and anti-angiogenic factors in wound 
repair and cancer, there has been a need reported for reliable, quantitative angiogenic 
assays to screen for activity and to determine the biological mechanisms of action [6].  
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The in-vitro assays represent the resting (2D monolayer) or sprouting (3D tube 
formation) phenotype reminiscent of their in-vivo counterparts that show both injury and 
repair features. Similar to the angiogenic cascade, the induction process of the in vitro 
sprouting assay incorporates:  
(1) Preparation of aggregate of ECs (the spheroid) phenotype from 2D monolayer 
cobblestone structure,  
(2) Preparation of a 3D matrix of collagen gel (from collagen I fibers to form the 
macromolecular space), 
(3) Activating the resting aggregate of cells by the addition of a factor to be tested and  
(4) Monitoring by quantification, the physical changes in resulting sprouting  
Factor for stimulation of vessels
2D ball of cells Spheroid: 2D put in 3D 
environment forms vessels 2D layer of cells 
 
Figure 4: Simple sketch showing angiogenesis process from 2D monolayer to spheroid 
The process involves getting the 2D layer of cells in a synthetic environment and 
processing them to form the aggregate of cells called the spheroids. This aggregate of 
cells is assembled in a 3D matrix and is then stimulated to form the vessel structures. 
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1.3. Research Objectives 
In studying the various cases of defined angiogenic process and its modification, it was 
important to be able to develop a synthetic (in vitro) production model representative of 
angiogenesis. This is due to the reason that animal models are considered extremely 
complex and difficult to interpret for routine screening and also relatively expensive [7].  
Addressing the current requirements, the in-vitro angiogenesis assay model was 
identified which was compatible with HTS. A production system is defined for this 
purpose. The spheroids which were the end product in this system were analyzed 
individually for detecting their performance parameters. This functions as a sensory assay 
to extract subtleties of high-content information using image processing software.  
The purpose was to adapt production of spheroids to a high volume assay. This required 
optimal design of the processes to ensure quality control. This production system was 
aimed to address the processes, identify variability, make the product, and validate its 
efficacy. The quality of the spheroid was achieved with validating the processes at 
different stages incorporating various control techniques. Standardized procedures were 
documented to provide for reproducibility. The validation of the assay performance was 
determined by variability assessment from the data obtained using the image analysis 
software. The validation technique was used to evaluate the multi-functional uses of the 
product to prove its robustness for various applications. 
Thus the critical part of the project being the production of the assay to repeatable 
numbers, also aims to illustrate the clear picture of software analysis for detecting the 
performance parameters of the product. 
1.4. Thesis Layout 
So far in the first chapter we stated the motivation for the current work and defined the 
need in the field of angiogenesis drug discovery. The thesis in the consecutive chapters 
defines the significance of the identified assay for the purpose of screening drugs in 
comparison to other assays. The detailed literature review on angiogenesis and the 
available assays for screening are elucidated. The uses of other assays and the versatility 
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of the spheroid assay in studying the behavior of spheroids to represent vasculature 
(blood vessel formation) are discussed. In detail description of the raw materials and their 
processing methods is illustrated. The material vendors have also been stated as a part of 
the assay protocol. Chapter three streamlines the protocols for the formulation of the 
assay from raw material to the screening stage. The chapter four continues to illustrate 
the value of the assay by showing the validation of the processes and also the powerful 
assay validation using the image analysis software. The chapter five discusses the results 
obtained from the analysis and their interpretation with respect to efficacy of the assay 
and its robustness. The assay application for screening a collection of plants is discussed 
in chapter six. It covers the validation of the assay when produced to screen a library of 
drug compounds for identifying any inhibitory activities. 
 
 
 
 
 
 
 
 
 
 
 10
CHAPTER II THE BIOLOGICAL ASSAY TO MIMIC BLOOD VESSEL 
FORMATION 
Bioassay or a biological assay is a type of in vitro experiment that is subjected to 
analysis. Bioassays are typically conducted to measure the effects of a substance on a 
living organism. Cell-based assays are one simplistic approach for such measurements. 
Bioassays may be qualitative or quantitative, the latter often involving an estimation of 
the concentration or potency of a substance by measurement of the biological response 
that it produces. Quantitative bioassays are typically analyzed using the methods of 
statistics [3].  
2.1. Existing Assays  
There is wide categorization of various in-vitro cell-based assays to assess response of 
EC to various agents and to study features mimicking in-vivo situation. A general 
classification of Cell-based assays for HTS [8]: 
1. second messenger assays that monitor cellular signal transduction 
2. reporter gene assays that monitor cellular responses at the transcriptional/ 
translational level 
3. cell proliferation assays that detect induction or inhibition of cell growth. 
Angiogenic cascade is a result of different steps. In this, the pre-existing vessels degrade 
their local basement membrane, migrate, proliferate, and subsequently align to form a 
network of new vessels which facilitates directional blood flow. These steps can be 
analyzed separately in different in-vitro assays [9]. 
In vitro angiogenesis assay system can be mainly categorized into migration, invasion 
and tube formation assays [10]. A brief description of the commonly used angiogenic 
assays is discussed further.  
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Two Dimensional Assays 
Classical in vitro assays representative of cell migration and invasion are Boyden 
chambers and Transwell filter chamber systems. The assays consist of upper and lower 
chambers separated by a filter to separate the two compartments. The extensive use of 
these assays has provided with understanding of the composition and function of cell-cell 
and cell-matrix adhesions [11].  
 
Migration Assay 
Migration (or chemotaxis) is the directional movement of cells in response to a 
concentration gradient of a soluble attractant. In migration assays, test cells are seeded 
into the upper chamber, a chemoattractant is added to the lower chamber, and cells that 
have traversed through the filter are quantified after an appropriate time span [10, 11].  
Migration is also detected by causing mechanical injury by scraping a confluent 
monolayer of cells. This mimics the lateral migration of EC from the wounded edge. This 
apparently is a classical non-directional chemokinetic experiment to determine the overall 
migration-regulating effect of a pharmaceutical test compound [9].  
 
Invasion Assay 
Invasion in addition to the migratory response requires for cells to express significant 
quantities of matrix degrading enzymes that digest the matrix barrier. This allows cell 
movement into and through the extracellular matrix. For observing invasion, the filter 
membrane is coated with extracellular compounds such as matrigel (which is a 
extracellular matrix from a tumor cell line [12]), so as to mimic the natural basement 
membrane (a surrounding environment in the matrix) [10, 11].  
 
The established assay systems have some inherent limitations. Each is restricted due to 
the fact that they only study individual steps of the angiogenic cascade such as migration 
or proliferation, invasion, etc. It has been investigated that they are not quantifiable of the 
angiogenic cascade because that they are cellular specific such as in a 2D Matrigel 
alignment assay. The Matrigel 3D assay is one common form of endothelial tube 
formation [5]. The study of the events in angiogenic cascade in separation may lead to 
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loss of high content information capture. Furthermore in 2D assay, the EC monolayer 
even grown to super-confluence in density, have limited proliferation rates and do not 
become perfectly growth arrested in vitro in order facilitate formation of vessels [9]. 
These considerations trigger the need for developing novel in vitro angiogenesis assays 
that may functionally and molecularly be more representative for the angiogenic cascade 
than the previously established experimental systems. To address the same, the latest 
investigation is done on 3D assays [9].  
Three-dimensional (3D) assays 
         
Figure 5: The biological product- spheroid sprouting stimulated with VEGF at 20ng/ml 
The current thesis concentrates on 3D tube formation assays. As observed in the recent 
years, one major advantage of 3D cell cultures is their well-defined geometry, which 
allows for inter-relation of structure to function. And apparently, techniques 
incorporating spatial resolution interpret promising data which can be stored and retraced 
[7]. In order to better mimic the in vivo situation, 3D assays are preferred to 2D assays as, 
the molecular mechanisms of cell adhesion and its functional contribution to cell 
behavior differs dramatically in three-dimensional matrices [13]. In this type of new 
culture system, the cells can be observed in three-dimensional matrices composed of 
extracellular-matrix (ECM) macromolecules. The widely used reagents which facilitate 
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formation of the 3D extracellular matrix are collagen, fibrin gels, matrigel [14], etc. This 
assay allows for implementing such a system to cell growth as well as the tube formation. 
It has been known that for tube formation, cells are grown in spheroids either alone or in 
co-culture with other cell types [11].  
It has been reported that the ECM provides the required scaffold for cells to organize and 
regulate their behavior [15]. Further investigation suggested that the physical state (such 
as structural and mechanical constraints) of the ECM and its molecular composition 
together, provides the relevant micro-environmental information regarding the cell-ECM 
interactions [16]. Recently simplified models of ECM using 3D matrices of type I 
collagen have been developed for understanding the ECM biomechanics [17]. In 
evidence, type I collagen polymerizes to form complex, 3D supra-molecular assemblies in 
vitro whose structure (in axial periodicity) is similar to those formed in vivo [18]. All 
these studies depict the relevance of in-vitro ECM to support the in-vivo like cellular 
phenotype.  
 
2.2. Significance of 3D ECSA (Endothelial Cell Sprouting Assay) 
In vitro primary EC usually cultured as two dimensional flat monolayers reflects most of 
endothelial in vivo phenotype properties. Yet in this phenomenon, the cells do not reach 
complete quiescence (stage representing cells resting phenotype, as mentioned in chapter 
one) which is needed for vessel formation. Studies have been performed to show that the 
multi-cellular aggregate spheroid model generates an inner area of quiescent cells. In 
order to keep the EC quiescent and to preserve their differentiation in vitro [3] the use of 
a novel method to culture EC as three dimensional spheroids has been adopted.  
The three-dimensional (3D) endothelial cell sprouting assay (3D-ECSA) is a very 
promising in-vitro biological assay model to study endothelial cell morphogenesis in 3D 
extra-cellular matrices. As mentioned, there being many other assays researchers use for 
angiogenesis screening, the assay recapitulates the angiogenic cascade and features the 
differentiation of endothelial cells into sprouting structures within a 3D matrix of 
collagen I [20]. It has been known that the sprouting assay can bring high-content 
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information on different aspects of endothelial cell differentiation, migration, invasion, 
tube formation and branching.  
 
The feasibility of this assay to be performed under well defined and controlled 
experimental conditions in order to analyse the EC functions makes it suitable for high-
throughput screening purposes. The laboratory started with the use of the assay for one 
plant and has discovered the compound called Withaferin A from the herbal plant 
Withania Somnifera. The WA has shown to have potent anti-angiogenic activities [39]. 
Since then it has been challenging to optimize the assay for screening a library of extracts 
and the software analysis helps statistical validation of the screening data. Thus the 
chosen assay has great potential for drug screening and validation so as to fill the gap 
between animal models and monolayer culture. The 3D ECSA uses the cellular 
aggregates called spheroids to depict the angiogenic process in the presence of an ECM 
scaffold made using the collagen. Exogenous growth factors can be added to the 3D cell 
culture to stimulate the growth of vessel-like structures that grow out from the spheroid 
and the drugs that inhibit sprouting can be tested. 
 
2.3. Materials  
Reagents, Material and Apparatus used 
S.No. Reagent Name Concentration Company 
Catalogue 
# 
1 Medium 199 1X GIBCO 
12350-
039 
2 Antibiotic/Antimycotic 100X GIBCO 
15240-
062 
3 Trypsin-EDTA 1X GIBCO 
25300-
054 
4 
Low Serum Growth 
Supplement(LSGS) 50X Cascade Biologics S-003-10 
5 Phosphate Buffered Saline 7.4,1X GIBCO 
10010-
023 
6 Paraformaldehyde 32% 
Electron Microscopy 
Sciences 15714-S 
7 Fetal Bovine Serum   GIBCO 
26140-
079 
8 
Methyl 
Cellulose/Methocel(MCS) 
4000 
centipoise FisherScientific M352-500
Table 1: Reagents used 
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 Plastic/Glass 
Ware       
S.No Name Company Catalogue # 
1 60mmx15mm Tissue Culture dish  Corning 25010 
2 100mmx15mm Petri dish Falcon 351029 
3 15 ml Centrifuge tube Fisherbrand 05-539-1 
4 50ml Centrifuge tube Fisherbrand 06-443-19 
5 115 ml filter system Corning 430944 
6 50ml Reagent Reservoir Costar 4870 
7 2ml Freezer vials VWR International 16001-102 
8 Boxed pipette tips rack 200-1000 μl Genemate P-3249-2 
9 Boxed pipette tips rack 0-10 μl Genemate P-3245-3 
10 Boxed pippette tips rack 20-100 μl Genemate  P-3259-200 
11 Pipettes 0-2 ml Falcon 35-7507 
12 Pipettes 0-5 ml Falcon 35-7543 
13 Pipettes 0-10 ml Falcon 35-7551 
14 Pipettes 0-25 ml Falcon 35-7525 
15 
Flat Bottom 96-well cell culture 
cluster Costar 3595 
16 2 ml vials Fisherbrand 05-408-140 
17 500 μl vials Fisherbrand 05-408-120 
18 9" Pasteur pipets Fisherbrand 13-678-20D 
19 Glass funnel     
Table 2: Plastic/Glass ware used 
Apparatus Used Company 
1 Pipettors(2 μl,200 μl, 1000 μl) Genemate 
2 Multi-Pipettors(2 μl,200 μl, 1000 μl) Genemate 
 3 Pipet-Aid Genemate  
4 6R Centrifuge Beckman Coulter-Allegra 
5  Mixer Thermolyne 
6 Waterbath-Isotemp 20 Fisherscientific 
7  Stirrer/Heater Thermolyne 
8 Push button counter   
9 Hemocytometer   
10 Microscope Nikon 
Storage Equipment   Miscellaneous 
Liquid Nitrogen tank Thermoforma Parafilm M 
Laminar Flow Hood Thermoforma Scissors 
Humidified Incubator at 5% CO2 37○C  Thermoforma Kimwipes 
 - 86○C ULT Freezer Thermoforma Nitrile Gloves 
Table 3: Equipment and other miscellaneous used 
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2.3.1. Biological Supplies 
There are three biological materials which are processed separately toward the 
assemblage of all. They are the HUVECs, Spheroids, Collagen. Each one’s preparation is 
discussed in detail in the methods section. 
HUVECs: A major advantage of cell culture is the ability to expand the number of cells 
available by subculture. Cells supplied in 1ml vials are seeded on plastic substrata (60 
mm cell culture dish) at a relatively low density to attach on the surface. After they 
attach, they progress from sparse (low density) to subconfluent (medium density) to 
confluent stages (high density) of increase in cell density. Human Umbilical vein 
Endothelial cells (HUVECs) were used in the assay because they are primary cells of 
human origin bringing relevance to disease and are readily available in large supply.  
 
Collagen: Collagen is an inert, rigid protein structure, inextensible in nature with good 
tensile strength. Type I collagen is the major structural component of extracellular 
matrices found in connective tissue and internal organs, but its presence has been studied 
to be most prevalent in the dermis, tendons, and bone. Its ability to strengthen blood 
vessels marks its use in the assay. It can be stored at its liquid state at 4o C and can be 
processed with the assay to spontaneously form the triple helix scaffold at a neutral pH at 
37o C [22]. This provides the solidified extracellular matrix for the spheroids in vitro. 
In order to get the quality end product, all the process stages should compliment one 
another and there lies the true value of the assay. 
2.4. Methods 
2.4.1. Cell culture - HUVECs 
HUVECs (Cambrex Bioscience) were cultured in 1X M-199 medium (Gibco), 10% Fetal 
Bovine Serum (FBS) (Gibco), 0.1 mg/ml of Antibiotic/Antimycotic (Gibco) and 0.2 
mg/ml of 50X Low Serum Growth Supplement (Cascade Biologics), at 37 °C in a 
humidified incubator with 5% CO2 and 95% air. 
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This culture mixture was called as the complete medium. Cells were used within the sixth 
passage. Medium was changed every 2-3 days and confluent dishes were split at 1:2 ratio 
using 0.05% trypsin-0.02% EDTA in HBSS (Gibco) 
 
2.4.2. Collagen Preparation 
Collagen type I was internally prepared in the laboratory. Rat tails from healthy young 
rats were used. In a 1 ml beaker, three tails were immersed in 70% ethanol solution for 15 
minutes and washed and re-immersed for a period of 1 hr. After they have been sterilized, 
using two forceps, one in each hand, the tail is held without exerting pressure. The tail is 
broken apart and pulled to separate in two parts. Tendons are extracted and immersed in 
clean ethanol for 20 min [9]. Ethanol is decanted carefully and the tendons are submerged 
in 250 ml 10% acetic acid. The solution is stirred thoroughly for 48 hours at 4o C. Later 
the solution is centrifuged at 2500 rpm at 4o C for 1 hr. The supernatant (without the 
debris) is decanted carefully and stored at 4o C in sterile bottle. Concentrated stock 
solution of collagen is thus obtained. The solution was checked for its pH to range from 
3.9-4.3 and was diluted as necessary in sterile acetic acid solution [5]. The collagen stock 
should be left to mature for 4 weeks before its usage so as to keep the EC baseline 
sprouting low [9]. 
 
2.4.3. Methocel Preparation 
In a glass bottle, add 3 gm of Methyl Cellulose powder (4000 centipoise) to make up a 
total volume of 250 ml in Medium 199. Place a magnetic stirrer in the bottle, loosely 
close the lid and autoclave it under gravity mode in an autoclave. Later, add 125 ml of 
M199 to the bottle and let stir for 20 minutes. Then add 125 ml of M199 and put to 
stirring in the cold room (at 4o C) for two hours. Store at 4o C. 
 
2.4.4. Cell count to generate spheroids 
Once the HUVECs reach the sub-confluent to confluent stages of growth, they were 
considered ready to be utilized for spheroid generation. This monolayer of cells attached 
on the surface of the dish was dissociated from the substrate surface with addition of 
proteolytic enzymes contained in Trypsin-EDTA solution, which leaves the cells 
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themselves intact and afloat in the medium. The cells in the trypsin-medium were 
collected and counted for their total density on a Hemocytometer. HUVECs were re-
suspended in the fresh complete medium containing of 10 % Methocel to generate the 
spheroids. Methocel acts as inert viscocity modulating substance by preventing cell-cell 
adhesion [23].  
2.4.5. Spheroid Generation 
The hanging drop method was used to generate a multicellular spheroid [24]. HUVECs  
suspension were diluted to obtain a concentration of 1x105 cells/ml. HUVECs 
suspensions of 10 μl (containing 1000 cells) droplets were then spotted on a non-adhesive 
100mm polystyrene Petri dish. Upon inversion of the dishes over the bottom plates 
containing 12 ml of sterile phosphate buffered saline (PBS) solution, the hanging drops 
were held in place by surface tension, and HUVECs were accumulated at the liquid air 
interface [25]. The spheroids were incubated for 24 hr at 37 oC in 5% CO2.  
 
2.4.6. Neutralized Collagen Mixture Preparation 
The clear collagen stock solution was collected from different rat tails and these batches 
were stored at 4o C. The collagen stock stored in a separate tube is degassed on the ice 
bath before every use to get rid of any dissolved oxygen content. To obtain a neutral pH 
collagen solution 10x M-199 medium (Gibco), 0.2 N NaOH, Collagen stock, 1:1000 
diluted solution of sterile acetic acid and 50 mg/ml NaHCO3 were gathered on an ice 
bath. Required numbers of 15 ml centrifuge tubes were pre-cooled for 2 min in the ice 
bath. The mixture of collagen is prepared by adding the reagents in the tube in the order 
mentioned above. While preparing the mix, reagents were thoroughly and gently mixed 
using the 1000 μl pipette (P1000) with the addition of every reagent, extreme care was 
taken not to generate any bubbles in the mix. The pipet-aid was set at low speed while 
making collagen mixture. 
 
2.4.7. Three-Dimensional Endothelial Cell Sprouting Assay (3D-ECSA) 
The endothelial spheroid assay [23] was adopted with some modifications to fit the 
experiment model. With the generation of spheroids and collagen mixture prepared, the 
assay was assembled with all components in the 96-well plate.  A bed of 50 μl of 
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neutralized collagen I solution was formed in separate 96 well-tissue culture plates 
(Falcon) and polymerized by incubation for 30 min at 37o C. The spheroids were 
collected in PBS solution and centrifuged at 300 rpm for 3 min, the supernatant was 
removed and spheroids were carefully re-suspended in an ice-cold solution of neutralized 
collagen type I obtained from rat tails [17]. Next, 50 μl neutralized collagen-I containing 
equal number of HUVEC spheroids was then distributed over this solidified matrix bed 
and newly added collagen was polymerized at 37o C. An aliquot of 50 μl of culture 
medium containing 10% FBS was added to each well. To induce sprouting, 20 ng/ml of 
vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) 
(Sigma) was added to the medium. HUVEC-derived spheroids were incubated at 37o C in 
5% CO2 for 24 hr. Sprouting was visualized with an automated Nikon TE2000E2 
inverted microscope, Photometrics digital camera and Metamorph software at 10X 
objective Digital images were imported to software for analysis of sprouting parameters.  
2.4.8. Extracts from Plant leaves 
Plant leaves from a wide range of species belonging to Kentucky native plants were collected 
from the Arboretum and stored at 4o C. Plant families belonging to Trees, Shrubs, Vines, Woods, 
Wildflowers and Prairie were collected and screened in the process. 
The plant leaves were homogenized and dissolved in Ethyl Acetate to extract the supernatant. 
The ethyl acetate extract from all plants collected was dried using the Genevac Evaporator and 
further also vacuum dried. The dried extract was dissolved in DMSO and stored at -20o C.  
 
 
 
 
 
 
*Supernatant: the clear fluid above a sediment or precipitate
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CHAPTER III ASSAY OPTIMIZATION 
 
 
PRODUCT DEVELOPMENT 
ASSAY 
OPTIMIZATION 
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PERFORMANCE 
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PROCESS 
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OF THE ASSAY 
ALONG WITH 
PROCESS 
VALIDATION 
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VALIDATION BY 
MEASURE OF 
THE 
PERFORMANCE 
METRICS 
Figure 6: Product development schematic 
3.1. Designing Process Development stages for Product Development 
Attenuating concepts from general macroscopic view to developing microscopic work 
flow structure has been a critical part of the assay development. Assay developers quote 
that be it for basic research or clinical purposes, an assay’s intended use becomes the 
anchor to which all optimization and validation activities are set. Optimizing an assay 
involves choosing its optimal format. Subsequently, the performance characteristics of an 
assay such as reliability, stability and repeatability need to be defined [26, 27]. With 
defining these parameters, the assay is checked for its optimization until the performance 
metrics are established and there is confidence in the results that are obtained from the 
assay. The results obtained proceeds to assay validation. A wide scenario sketching out 
the three main stages in product development is shown in the figure 6. 
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This strategy can further be categorized into four modules  
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Figure 7: Schematic showing the overall research design and modules involved [28]. 
Product development consists of the certain phases. The first was to identify a model 
which fulfills the need. Addressing the first phase, the spheroid model using the 
HUVECs was adapted because of its compatibility to high-content screening and high-
throughput screening. The stages of validating the reliability of the assay has been 
conducted which is discussed in the next chapter.  The validation results certify that the 
assay is fit for use. Our purpose was to build a prototype of a powerful high content 
screening platform by interfacing high throughput screening capability with multi-
parameter optical imaging of endothelial cell patterning in the 3D matrices. The multi-
parameters established are discussed in the next chapter. 
Product development can be associated to the process validation of a reagent or 
component. The process design helps in establishing user requirements throughout the 
development process. Product conformance to specifications is checked throughout all 
stages of development. Thus the process validation is made product specific [29]. In our 
process, each well of the 96-well plate is considered a product. 
Once the process is designed, the process is validated statistically. Validation requires 
documented evidence that a process consistently conforms to the requirements. It is 
required to first obtain a process that can consistently conform to requirements and then 
run studies demonstrating that this is the case [30]. 
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In the stage of developing the consistent process, experimentation and root cause analysis 
for problem solving is performed. A Failure Modes and Effects Analysis (FMEA) 
involve listing out the potential problems or failure modes and evaluating their risk in 
terms of their severity, likelihood of occurring and ease of detection. Where potential 
risks exist, the FMEA can be used to document which failure modes have been addressed 
and which still need to be addressed. As each failure mode is addressed, the controls 
established are documented [30]. The end result is a control plan in the form of Standard 
Operating Procedure (SOP). Addressing the individual failure modes will require the 
necessary theoretical and experimental analysis. 
3.2. Standard Operating Procedures for Manual Processing 
The major part of the thesis deals with processing the assay to optimize and adapt it to 
high throughput screening.  The operating procedures for the product are discussed 
below: 
• Culture HUVECs in 60 mm culture dish over a period of two days from the time of 
seeding them in the ratio 1:2. The cells reach approximately 70% confluence based on 
cell passage number and other intrinsic biological factors.  
 
• Trypsinize HUVECs for 3 min in the incubator for the cells to dissociate from the dish 
surface. Later, perform 1:2 dilution of trypsin in complete medium to collect them in a 
centrifuge tube. Set the tube to centrifugation for 5 min at 750 rpm. Re-suspend in fresh 
complete medium and count for the concentration of cells. Then add Methocel (MCS) 
to make up the HUVEC medium. 
Cell count: After resuspending cells in complete medium, add a 20 μl droplet on one 
counting chamber of the Hemocytometer and center a cover slip between the mounting 
supports. Use the push button counter to count the number of cells on each of the 1mm 
x 1mm outer four squares. Take the average of the four readings and multiply the 
number to a concentration of 104. 
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 Figure 8: Hemocytometer showing the engraved cell counting surface on the chamber 
 
• The usage of single plate cells per experiment is maximized to making optimal amount 
of HUVEC medium by diluting the cells in the medium to reach the concentration 
1x105cells/ml. This concentration gives the required 1000 cells per droplet. Make up 
the following volumes based on the confluent stage of the HUVECs and add 10 % 
Methocel. For a volume of N, it is necessary to use N-1 plates for generation of 
spheroids to avoid any deformed spheroids caused due to insufficient amount of cells in 
the droplet. 
60 mm dish 
Confluence 
Volume (N) of 
HUVEC medium for 
spheroids+ 10 % MCS 
to be added 
Maximum number of 
spheroid plates (N-1)  
50 – 60 % 6 ml 5 
70 – 80 % 8 ml 7 
90 % 10 ml 9 
Table 4: HUVEC medium chart for generating 10 μl spheroid droplets 
 
• Formulation of Cell Media for Different Cell Concentrations/Optimizing to make up 
the Cell media to get 1000 cells per 10 μl droplet 
Required concentration of cells = 1000 cells/ 10 μl volume = 105 cells/ml 
From every plate of cells being used for generating spheroids, calculate the dilution 
ratio from the cell density count performed using the Hemocytometer. 
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Dilution Ratio = 
countdensityCell
ionconcentratquiredRe =  5
5
10x X
10  
Further, for ‘Y’ amount of medium used in resuspension, the volume of cells which 
gives the required 105 cells/ml, calculate Z = 
X
1000 x Y  ml of cells  
Now, in total of Y ml, the spheroid medium constitutes of Z ml + 10 % Methocel 
PolystyrenePetri dish  
                       
10 μl Droplet Inversion
Figure 9: Cells seeded in 10 μl droplets on Petri dish (6 nos. optimal) and inverted as 
hanging drop for generating spheroids to make up 1 96-well plate of spheroids. 
 
• Transfer HUVEC medium in a 50 ml reagent reservoir and using a multi-pipettor fill 
the surface of the lid of the Petri dish with 10 μl droplets as shown in figure 4. 
 
• The bottom portion of the dish is filled with 12 ml sterile PBS medium to maintain a 
humid atmosphere during the 24 hr period of incubation. 
 
• Generation of Spheroids – Hanging drop model 
The cells are encapsulated in the form of a hanging droplet. A stable 3D multi-cell 
spheroid is formed within 24 hr of cultivation to the size of about 100-150 μm [22] in 
diameter. The spheroids organize over time (1d) to establish a core a quiescent 
unorganized cells and an outer layer of quiescent, non proliferating surface monolayer of 
endothelial cells [9].  
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0 hr 4 hr 12 hr 24 hr  
Figure 10: Spheroid shown with time course formation 
• Collagen mixture and plating primary layer of collagen on the 96-well plate  
It is preferable to set the pipet-aid at low speed while making the mix. Prepare Collagen 
mixture on ice as mentioned earlier, in appropriate ratios to make up the required volume 
for plating the 50 μl primary bed of collagen in the 96-well plate. Let plate to polymerize 
at 37o C for 30 min. 
 
Collagen ratio chart is followed for making up different volumes (in μl) 
 
  A B C D E F G H I J K L 
10X M199 100 200 250 300 350 400 450 500 600 700 800 900 
0.2 N NaOH 94 188 235 281 328 375 422 469 562 658 750 843 
Collagen 
Stock 500 1000 1250 1500 1750 2000 2250 2500 3000 3500 4000 4500 
1:1000 Acetic 
Acid 500 1000 1250 1500 1750 2000 2250 2500 3000 3500 4000 4500 
Sodium 
Bicarbonate(1-
10 μl)   1 1  1  1  1  1  1  1  2  2 5  5  
Collagen 
Mixture Sum 1000 2000 3000 3500 4000 4500 5000 5500 7000 8000 9500 10500
Ratio 
Ingredient 
Table 5: Collagen chart for making the collagen mixtures in required volumes 
Based on the required final volume of the collagen for a single use, the respective ratio is 
selected (for one 96-well plate of 50 μl per well, ratio G is optimally used). 
 
• Batch Harvesting 
After the 24 hour period formation of spheroids in the drops, collect spheroids from the 
dishes using 3 ml PBS per dish. Using a glass funnel, in batches of 3, transfer the 
spheroids with PBS into a 50 ml centrifuge tube for each set to make a 96-well plate. 
Centrifuge the tube(s) for 3 min at 300 rpm. 
 26
 • Seed Spheroids with Collagen  
Place the centrifuged spheroid tube(s) on ice. On ice, make the collagen mixture (avoid 
making any bubbles by setting pipette aid at low speed) in pre-cooled 15 ml tube for the 
required amounts to seed spheroids in a 96-well plate. Considering the spheroid delicacy 
and not to damage them, cut the 200 μl pipette tip to 5 mm distance. On the ice bath, 
collect the contents from the tube with a tip-cut 1000 μl pipette, using cold collagen and 
transfer onto a 50 ml reservoir. Using four 200 μl tip cut pipettes on a multi-pipettor, 
dispensing the collagen-spheroid medium from the well walls, seed the spheroid-collagen 
medium on the solidified primary bed of collagen in the 96-well plate. Extra care needs to 
be taken while working on ice to make sure collagen does not polymerize while in 
working conditions. 
                               
Solidified primary 
collagen bed Spheroid 
                                         
Figure 11: 96-well plate map, schematic and true color image of spheroid embedded in 
collagen 
 
• Incubate the 96-well plate at 37o C in 5% CO2 for 1 hr to ensure uniform collagen 
polymerization across all wells. 
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• Map the plate according to the treatments. Add respective treatments, in the wells to 
make up a total volume of 200 μl in each. Incubate for a period of 20-24 hr. 
 
• Fix plate using 50 μl of 4 % paraformaldehyde and seal with strip of parafilm and store 
at 4o C. 
 
• Capture digital images corresponding to respective treatments in each well using the 
automated Nikon TE2000E2 inverted microscope, Photometrics digital camera and 
Metamorph software at 10X objective lens. 
 
• Use image analysis software to process the images and collect data 
 
It might of interest noticing the changes made with respect to the process that existed 
earlier. I have tabulated the previous to current processes as under 
 
 
Previous Current 
4 plates of spheroids for 1 96-well plate 6 plates of spheroids for 1 96-well plate 
40-50% loss in yield of spheroids 50% loss in yield of spheroids 
20% loss of spheroids in the 96-well 
plate less than 10% loss of spheroids in the 96-well plate 
30 μl of each collagen layer 50 μl of each collagen layer 
20% of Methyl cellulose 10% of Methyl cellulose 
Transfer using tip-cut pipet Transfer using funnel- Saves 50% time  
Separate PBS used for washing PBS from the bottom plate of petri dish used for washing
96-well plate experiments 
96-well plate experiments and pilot studies on 384-well 
plate 
 384-well plate results: 
 labor some manual image capture 
 volume of reagents reduced to 4 times 
 more bubble formation 
 Pilot studies on: spheroid generation 
 
U-bottom spheroids, V-bottom spheroids, Pipet hanging 
drop spheroids, Bead spheroids 
Table 6: Previous process and current and experimented processes 
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3.3. Safety  
A scientist or a manufacturer should evaluate all factors that affect product quality when 
designing and undertaking a process validation study. Under this, the safety factors are 
considered such as air and water handling systems, environmental controls, equipment 
functions, bio-hazardous disposal and treatments along with other process control 
operations. A laboratory, similar to a manufacturing industry thus conducts vigilance on 
safety concerns for maintaining a contamination free environment in biological working 
conditions.  
Proper Hood Usage and Waste Handling to avoid contamination are listed as under: 
1. Make sure the blower is switched on while working and keep window up atleast 6 
in. 
2. Weekly empty the biohazardous material in aspirator flasks after treating with 
bleach. 
3. Wipe hood area and glass shield with alcohol (70% ethanol) after every use while 
the blower is still running. 
4. Spray alcohol on items that are placed in water bath before being used under the 
hood. To reduce corrosion and deposition of salts from water, occasionally 
change water in water bath. 
5. Check on water in the humidifier container inside the incubator. 
6. Empty all orange disposal bag containers and replace orange bags weekly. 
7. Check on Nitrogen tank buffer so as to replace when the incubator runs low on 
supply level. 
Inventory Maintenance 
A minimum buffer of one was maintained for all reagents used by updating stock reorder 
requirement on a board accordingly 
1. A minimum buffer of plastic supplies was maintained at 10 
2. A minimum buffer of 3 vials was maintained for HUVECs 
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3. Liquid Nitrogen level was checked monthly and recorded on a chart every time it 
was filled. 
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CHAPTER IV ASSAY VALIDATION 
Assay Validation: Validation can begin only after the assay design is set and the test 
parameters have been established. In our assay validation, we have modules to separately 
validate the process and the product. Based on the data obtained during the development 
phase and with the help of sound judgment, a validation protocol is prepared. Various 
statistical practices in assay development reported that such a protocol should include 
experiments that confirm those assay parameters deemed important during the design 
period and test whether the device meets the performance criteria for its intended use 
[31].  
  
4.1. Biological process validation  
4.1.1. Variation in a manufacturing system 
In every manufacturing operation there is variability. The variability becomes evident 
whenever a quality characteristic of the product is measured. Quality control systems 
focus on conformance of the product to its stated functionality and specifications. This is 
expressed in terms of statistical measures and the degree of variability is exhibited. The 
variability in measures of the physical characteristics of the product such as its 
dimensions, color, or structure, etc is viewed having two general causes: assignable and 
common. Assignable cause variation is associated with one or more particular factors 
and the relationship is known in terms of both direction and magnitude for each of these 
factors. Common cause variation cannot be associated with particular factors instead is 
viewed as related to the collective impact of many factors. The relationship of any of 
these factors to a particular factor is not precisely known and cannot be directly 
controlled [32].  
It is important to learn how much of the product variability is actually inherent in the 
process. Many factors influence a process and each contributes to the inherent variation 
affecting the resulting product [33]. Common causes of variation are often considered to 
lie hidden within the system, and are sometimes assumed to be unavoidable. Yet it is very 
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possible, and often very rewarding, to improve processes and reduce common cause 
variation [34]. This is what has been aimed in my work. Typically, this type of variation 
requires a long-term strategy to identify, understand and reduce it through on-going 
process management and improvement (G.Tennent). With the required knowledge base 
amongst the people in and around the process, many ideas for improvements can be 
generated to make a significant impact. Two well-known ways to search for and remove 
common causes are experimentation and stratification [35] or a combination of both. 
Under experimentation model, the PDCA (Plan-Do-Check-Act) cycle calls for creative 
thinking and analytic thinking, both essential to guide process improvement that brings 
the scattered pieces back together in a workable form. As it is usually used for process 
improvement, the search for common causes is just one of the many arenas in which the 
PDCA cycle can be used [35].  
Stratification often needs to be done iteratively from a general level of information to the 
data at different levels, which brings visibility to the links between levels. This sorting of 
data into multiple levels of groups with shared characteristics, helps interpret the root 
cause of a problem. Even the cause and effect diagram could be used to build a tree of 
branching characteristics, each one being stratified further and further until root causes 
are reached [35]. We will see next, how incorporation of these methodologies can help 
identify process errors and validate them. 
4.1.2. Process validation 
The standardized process has been mentioned in the previous chapter. Here we discuss 
various parameters influencing each process and how it affects variability. Cause-and-
effect diagrams permit assessment of factors important to measurement that may go 
beyond the process flow diagram. For each control point, various factors which can affect 
that control point with a resultant affect on the value of the product were identified using 
brainstorming sessions. Once all the elements of the diagram were identified, the ones 
which could be readily controlled were identified and results were measured [34].  
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Figure 12: Process flowchart and cause-and-effect diagram labeled with the possible 
variable parameters at every process. 
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An FMEA is systematic analysis of the potential failure modes. It includes the 
identification of possible failure modes, determination of the potential causes and 
consequences and involves an analysis of the associated risk. It also includes a record of 
corrective actions or controls implemented resulting in a detailed control plan. FMEAs 
can be performed on both the product and the process. Typically an FMEA is performed 
at the component level, starting with potential failures and then tracing up to the 
consequences. This is suggested to thus be a bottom up approach [36].  
The generation of spheroids has been optimized. Yet, the consideration for the yield of 
spheroid is not accounted in the sense that 40-50% of spheroids are lost during the wash 
and the transfer process to the 96-well recipient plate. This is an inherent overall loss, 
control of which has not been determined. 
 
Though for validating the processes, pilot studies were conducted for the following 
processes: 
 
1. Spheroid formation 
One of the main processes in the assay is to form the spheroid component. Hanging drop 
cell cultures were incubated. The gravitational force exerted on the cells in the hanging 
drop suspended cultures caused sedimentation to begin, and aggregates were formed 
within the first 24 hr. After sufficient sedimentation time, the resulting cellular aggregates 
were harvested. The two-dimensional aggregate prepared by hanging drop sedimentation 
assumes a three-dimensional spherical morphology after transfer to a collagen ECM [37]. 
Significance of wash process: 
• Cleans spheroid from the extra cell debris  
• Quality measure for spheroid formation 
 
The quality of intact spheroid formation is tested in the process of washing and 
harvesting them. A comparison of 12 hour spheroid formation versus 24 hour spheroid 
formation was performed. It was observed that the 24 hour spheroid formation is more 
resistant to wash and a team member first observed there was a ring formation on the 
periphery of the spheroid surface. We consider this ring as a validating factor for the 
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spheroid formation. Few images of 24 hr spheroids under wash are shown below. With 
this process, only those healthy spheroids which survive the wash process are taken to the 
next stage thus ensuring a quality component flowing downstream.                        
 
Figure 13: Spheroids shown in the wash and collection process  
The spheroid(s) after the wash to get rid of the external debris of cells remain intact 
which can be transferred onto the 96-well receptacle plate 
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Figure 14: The number of spheroids lost on plate after single wash for different 
experiments is plotted here.  
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The number of spheroids lost on the plate varied depending on how well the spheroids 
were collected. Out of the 40-50% loss of spheroid yield, around 10% is loss in the 
harvesting process. Yet this loss does not influence the value of the end product. The 
return attained with the analysis of the end product was more than the investment in this 
process. The control was to rewash the plate to ensure maximum collection. Yet it was 
important to remember, the more aggressive the wash process, there was a probability to 
loose spheroids due to their getting damaged. The control of which was not determined 
yet but it doesn’t affect the system overall and was less accounted as long as I (operator) 
was able to deliver quality spheroids onto the receptacle 96-well plate. 
2. Collagen polymerization  
 In the subsequent stage, collagen mixture is prepared. Its polymerization is an 
irreversible process and thus the structure ceases to polymerize once disturbed. 
Temperature controls need to be maintained at 4o C. Many controls have been 
incorporated as mentioned in the SOP in the previous chapter, to ensure uniform collagen 
polymerization. Collagen is a transparent layer in the 96-well plate which is gelled at 37 o 
C. Its polymerization level determines the quality imaging of the spheroids. A non-
polymerized layer not only makes the spheroid view opaque under the microscope, but 
has also been observed to disrupt the sprout formation in some cases. Once the right 
working conditions are ensured, the use of high quality microscope at 10X magnification 
helps in good image capture of the spheroids.  
 
Controls incorporated to ensure uniform polymerization are: 
*the right insertion of pipettes in the multi-pipette holder 
* maintain all material used for preparation of collagen bedding at or close to 4o C 
3. Bubble formation  
Forming bubbles in the collagen layer is another potential defect. Ensuring right working 
conditions (according to SOP) helps avoid generating bubbles. Though user variability 
has a lot to do with the process, one possible factor has been identified and validated. On 
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the same lines, statistically, it has been observed one out of 10 plates has bubbles in its 
wells and that one plate contains around 5-20% wells with bubble formation.  
Controls: 
• The collagen was degassed to remove any dissolved oxygen content. 
•  Dispense collagen at an approximate 45 degree inclination of the pipettor. For 
first layer make sure the collagen dispensed covers the entire surface of the wells. 
For the second layer, using tip-cut pipettes dispense collagen (consisting of 
spheroids) gently from the well walls and by trying not to touch the primary 
collagen bed with the tip. Usually I would recommend pipette introduction into 
the wells to distance not more than 15 mm. 
 
Figure 15: A well with no bubble and a well with bubble among the spheroids seeded in 
collagen              
One way of validating the bubble formation was by the comparison of pipette tip-cut 
distances. There was a 40% decrease in the bubble formation when 5 mm distance tip cut 
pipettes was used in comparison to using a 10 mm distance tip-cut pipettes and with the 
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collagen dispensed from the well walls.                                   
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Figure 16:  Bar graph showing 40% reduction in bubble formation when 5mm tip-cut 
pipette was used. Error bars show there is significant difference in values which is 
confirmed by Ttest with p<0.05 
 
 
Figure 17: The figure above shows the spheroid from initial formation to the assembly 
stage in the 96-well plate.  
Thus the problem solving helped optimizing the process at different stages and was 
checked for validation.  
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3. Screening stage 
 
In the final stage, the treatments were added per well with reagent mixture consisting of 
1X M199, 5 % FBS and 0.025 mg/ml Antibiotic/Antimycotic. This is the stage that adds 
true value to the product with the addition of treatments based on a set hypothesis. This 
process needs to be quality controlled to ensure zero defects. Simple mistake proofing 
methods were adapted. The 96-well plate map was used as the visual control marking all 
the necessary treatments on the map and used as visual control during the addition of 
treatments. The Go, No-go gauges were the images of spheroids with sprouting and no 
sprouting. Typically for drug screening Go gauge is considered to be the spheroid with no 
sprouting. The images of the spheroids are shown below.  
 
 
No Sprouting Sprouting 
Figure 18: Treatments showing sprouting and no sprouting spheroid images 
There is variation in a process even when all adjustable factors known to affect the 
process have been set and held constant during its operations [33]. The inherent 
variations result as the end product with the level of spheroid sprouting. The parameters 
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for the spheroid sprouting are measured using the image analysis software and the 
variation is determined using normal distribution graphs (shown in the Results section). 
Assay Lean features: 
• Low lead time of four days  
• The concentration of volume of reagents is optimized, as in a manufacturing 
process. Assay performance is also enhanced by the use of specially treated 96-
well plate which has specific surface properties that assure even coating and 
minimize the meniscus formation [10]. 
• Replication allows a researcher to estimate experimental error. If the magnitude of 
experimental error is unknown (which happens if it cannot be estimated), then a 
researcher cannot determine whether any effects or interactions are statistically 
significant. This also allows a tolerance to the spheroids analyzed by eliminating 
the false positives *. 
• The assay is not complete before the addition of necessary treatments in desired 
doses.  This gives the assay a lot of variety to incorporate based on the experiment 
designed. The 50 μl of medium alone without any treatments can be added after 
the collagen second layer polymerization process. The addition of next 50 μl 
treatment variety is incorporated in the end. Thus, the assay is similar to having 
“postponement of variety approach”.  
• All the initial stages of the process are standardized and controlled and any 
inherent variability can be recognized by problem solving methods. 
• The overall length of the assay was not be substantially shortened by this process, 
but the volume of samples that can be tested and analyzed using this strategy 
allows numerous conditions to be tested in a single run. 
 
 
*False positive: The spheroid which turns positive for wrong reasons, such as due its health or interaction 
with the microenvironment (collagen matrix) 
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4.2. Software Validation  
Simple measurement of the growth or shrinkage of spheroid sprouts was accomplished by 
microscopy and computer image analysis. A microscopy system was configured to 
reading the assay and taking the photographs (currently being worked in a manual mode). 
Our collaborator with his experience in pattern recognition, in the project has applied 
wavelet analysis and thresholding to get rid of noise components in the measurement of 
spheroid. The tubules of the spheroid were segmented from the background by searching 
the one-dimensional wavelet sub-bands looking for peaks in amplitude that exceed the 
noise level defined according to the largest radial rings. These signals out the noise were 
considered to result as tubule measurements.  
With the individual tubule components identified, the collaborator and his team were able 
to monitor the growth metrics such as number of tubules, average and total length of 
tubules, average tubule width and the total area covered by the tubules. The software 
developed so far, does a good job in determining up growth parameters mentioned. Their 
analysis is further intended to trace for count on tubule branching, another growth metric 
which measures the spheroid behavior in the formation of vessels. The sprouts were 
imaged using an inverted microscope and digital camera to photograph spheroid in each 
well. The scripted software processed the images for number of tubules, length and width 
of sprouts and the total area [28].  
The assay can be performed two-way. The one discussed was the regular method and 
involves rapid screening, by testing the effect of drug in the presence of any stimulating 
factors. If the drug compound overcomes the growth promoting action of angiogenesis 
stimulator, then inhibition of any possible tube formations was observed. The second one 
was significant for studying the effect of drug compounds on already existing vessel 
formations. In this the growth factors were incubated with spheroid for 24 hr to induce 
sprout formation and respective wells were photographed (without the fixation of 
sprouts), followed by the addition of drug compound for the next 24 hours. If the drug is 
a positive for inhibition then it is called a hit or active compound (where active means 
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some measurable activity below the control threshold of the assay) [38] and the pre-
formed tubes are observed to collapse. 
 
4.3. Variability assessment – inter plate, inter day, dose response assessment 
 
A manufactured product needs to be assessed for the consistency in its repeatability. 
Usually in industries, products are checked to meet the specifications using the sampling 
approach. The variability assessment performed here also similarly samples out a bunch 
of spheroid data and gives a representative performance measure. With no automation 
involved in the product-development stage, the inter-plate, inter-day variability 
assessment consists of consecutive, independent experiments measuring assay responses 
collected for evaluating the coefficient of variation (CV). The most informative data will 
then come from experiments done on separate days with independently prepared 
reagents. 
A typical layout for the 96-well plate is shown as under. Treatments were added in 
different wells as designed in singles or replicates, etc. and the plate is well mapped for 
identification of treatments and to label the respective images of spheroids for analysis 
based on well number as mapped. 
 
Well numbers by 
row, then column                         
 Column/ Row       1 2 3 4 5 6 7 8 9 10 11 12
A 1 2 3 4 5 6 7 8 9 10 11 12
B 13 14 15 16 17 18 19 20 21 22 23 24
C 25 26 27 28 29 30 31 32 33 34 35 36
D 37 38 39 40 41 42 43 44 45 46 47 48
E 49 50 51 52 53 54 55 56 57 58 59 60
F 61 62 63 64 65 66 67 68 69 70 71 72
G 73 74 75 76 77 78 79 80 81 82 83 84
H 85 86 87 88 89 90 91 92 93 94 95 96
Figure 19: A 96-well plate mapped with numbers for identification 
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For the assessments, we have sampled sets of spheroids to determine variation from well-
to-well, plate-to-plate; two-day plate readouts and the metrics were calculated using the 
software analysis of the spheroid images. 
As part of validating assay variability the assay reagents along the assay components 
need to be checked constantly. It is important to determine the stability of reagents under 
storage and assay conditions. 
Reagent Stability and Storage Requirements 
• For commercial products, use the manufacturer’s specifications for the reagents.  
• Identify conditions under which aliquots of the reagent can be stored without loss 
of activity. The fresh growth factors aliquoted in volumes of 10μl/vial were stored 
at -20o C. After the initial thaw they were stored at 4o C. After this, the growth 
factors cannot be used more than 3 thaw cycles. 
• Test compounds/extracts were delivered at fixed concentrations in 100% DMSO 
(Dimethyl Sulphoxide), thus solvent-compatibility of assays in DMSO was 
determined. Typically the final concentration of DMSO in the assay was 
maintained below 2%. 
• The drug compounds were stored at -20o C and thawed for stipulated time before 
every use. 
• Be sure not to contaminate any reagent while thawing in the water bath. 
4.4. Results on stimulatory responses 
Variability assessment was performed for various assays on different days. The NIH 
manual for validating the assays was approached in our attempts. The following are the 
results from the assay plates. As a part of quality control measure for the spheroid culture 
module, I sampled sets of spheroids to determine variation from well-to-well, inter-plate 
and inter-day. Various growth metrics identified for analyzing the spheroid behavior were 
total number of tubules, total length of the tubules and total area of the tubules, average 
length, maximum length and average width of tubules. These measures of the parameters 
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show the inherent variability in the product performance as defined by the above 
mentioned parameters.  
        
Figure 20: The graphical user interface of the software for calculating the performance 
parameters. 
1. Well-to-well (product to product) variability assessment 
Well to well variability assessment was performed to check for the consistency in the 
replicated spheroid samples in each well. The validation results show that there was 
consistency in values across all the growth metrics measured. The p-value for the 
parameters in the assay was calculated. In the data analysis values it was found that for 
average length, maximum length and average width of the tubules p>0.05 from the 
student’s t-test which shows that there is no significant difference in those values of the 
parameters.  It was preferred to consider the total number of tubules, total length of the 
tubules and total area of the tubule to be significant in terms of validation.  
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Figure 21: Graphs showing well-to-well variability assessments for all the defined growth 
parameters. 
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2. Inter-plate variability assessment 
Initial plate to plate assessment was performed with inducing sprouts in spheroids to 
compare the two growth factors called the Vascular Endothelial growth factor (VEGF) 
and Fibroblast growth factor (bFGF). VEGF and bFGF are two proteins commonly 
known for sustaining tumor growth and are thus used as injury stimulating models in our 
in-vitro assay. This assay showed that statistically there was no difference in the 
performance parameters of the spheroids stimulated with either of the two growth factors. 
This was considered as the initial experiments of validating what was scientifically 
already known using the assay’s performance parameters. 
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Figure 22: Statistical interpretation in comparison of two growth factors for stimulatory 
responses 
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3. Dose Response Assessment  
Day 1: Inter-plate comparison – VEGF Dose response Vs bFGF Dose response 
Dose variation experiments using VEGF and bFGF from doses 40ng/ml to 1.25ng/ml 
were compared to no growth factor (control) treated spheroids. There was significant 
increase in growth parameters when compared to the control and that is shown by 
*p<0.05. The different parameters are shown in respective separate graphical plots. 
3.1. VEGF Dose Response Parameters 
A set of doses representative images of spheroids treated with VEGF and the spheroid 
with no VEGF (control) are shown below. 
   
 
 
 
Figure 23: The dose response images of spheroids representative of VEGF doses from 
40ng/ml to 1.25ng/ml and the control (no growth factor) 
VEGF 40ng/ml VEGF 30ng/ml VEGF 20ng/ml VEGF 10ng/ml 
VEGF 1.25ng/ml Control VEGF 5ng/ml VEGF 2.5ng/ml 
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Figure 24: Graphs for VEGF dose response and comparison of growth parameters over 
the control. 
*p<0.05 
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The data from the above VEGF dose response graphs shows that for maximum length, 
total length and total area of tubules all the doses from 1.25ng/ml to 40ng/ml start to 
show significant differences over the control. This is not the case with average length and 
average width which show p>0.05 meaning there is statistically no difference in the dose 
response. For the total number of tubules the difference in values start showing up from 
the dose 5ng/ml over the control.  
3.2. bFGF Dose Response Parameters 
A set of doses representative images of spheroids treated with bFGF and the spheroid with 
no bFGF (control) are shown below 
    
    
FGF 40ng/ml FGF 30ng/ml FGF 20ng/ml FGF 10ng/ml 
FGF 5ng/ml FGF 2.5ng/ml FGF 1.25ng/ml Control 
 
Figure 25: The dose response images of spheroids representative of bFGF doses from 
40ng/ml to 1.25ng/ml and the control (no growth factor) 
The statistical analysis of the data plotted for all the growth parameters is shown below. 
For total length and total area the difference in doses starts showing from 2.5ng/ml over 
the control. Average width and maximum length do not show statistical differences in the 
doses while total number of tubules show differences starting from 2.5ng/ml over the 
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Figure 26: Graphs for bFGF dose response and comparison of growth parameters over 
the control. 
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Day 2: Inter-plate comparison – VEGF Dose response Vs FGF Dose response 
A similar experiment was set up on day 2 to trace the plate-to-plate variability in the 
assay. The comparison of the assay performance parameters from day 1 and an assay 
from day 2 will also give us the inter-day variability. 
3.3. VEGF Dose Response Parameters 
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Figure 27: Graphs for Day 2-VEGF dose response and comparison of growth parameters 
over the control. 
Doses 5ng/ml, 30ng/ml and 40ng/ml show statistical differences over the control when 
analyzed for the maximum length of the tubules. Average width and average length show 
no statistical difference. For the total area of the tubules, doses 5ng/ml to 40 ng/ml show 
difference over the control. For total number of tubules doses 2.5ng/ml to 40 ng/ml show 
difference over the control and for total length of tubules doses 1.25ng/ml to 40 ng/ml 
show difference over the control. 
3.4. bFGF Dose Response Parameters 
The parameters average width and average length show no statistical difference in the 
values. Total number, total length and total area differ over the control from 1.25ng/ml 
and above. Maximum length differs over the control only at the dose 30ng/ml. The 
graphs showing the results are plotted below. 
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Figure 28: Graphs for Day 2-bFGF dose response and comparison of growth parameters 
over the control. 
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4. From the dose response curves obtained, an optimized dose of VEGF/bFGF was set to 
20ng/ml. This dose was used for spheroids in treatment with drugs or plant extracts. The 
statistical measures are shown for a closer analysis on the total number and total length of 
tubules.
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Fig. 29 The graphs above for VEGF and bFGF treated parameters, show the increase in 
total number of tubules and total length of tubules to being a two-fold and confirm the 
significant difference in 20ng/ml treated values over the control with p-value<0.05. 
4.4.1. Summary 
The assay was quality inspected using the software tool. Performance inspection was 
performed and variability assessment graphs have been plotted. Here they are 
summarized: 
1. The assay was put to test by treating with two different growth factors at same 
concentrations and checked for the consistency in results.  
2. The assay was further tested for well-well variability assessment which showed that 
the spheroids behaved consistently when considered in large numbers. 
3. Next step in the validation was to perform, Plate-to-plate assessment of sprout 
formation when treated with VEGF and bFGF 
4. A dose response assessment was performed and the data showed consistent 
measurement in growth metrics for doses range between 40ng/ml and 2.5ng/ml. 
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This showed that even with a least amount (1.25ng/ml) of VEGF, tube formations 
are stimulated. This concentration response curve can be used for setting up an 
optimal amount of the growth factor for inducing sprouts when introducing various 
drug compounds. 
Growth assessment was performed with setting up a dose of 20ng/ml of the growth 
factor in compariso
5. 
n to no growth factor treated (here the control). 
The a and absence of a 
growth factor. 
rent angle, the assay can be used in interpreting the inhibitory responses. 
We can induce the spheroid assay with growth factor on the identified optimal dose 
For
control with stimulators (or the growth factors) alone and the other with the 
 factor for 
stimulating sprouts, without the drug/sample treatment (the control for the 
ii) 
e vessels are grown, the 
Another way of testing the assay was to subject spheroid assay to a treatment which 
restricts its growth. The next chapter shows one assay to study the behavior of the 
spheroid when treated in high glucose which causes suppression of tube formation and 
bove data shows the stimulation responses of the assay in presence 
6. On a diffe
(i.e 20ng/ml-call this the control here) and then compare the growth to a drug 
treated sample set of spheroids to see if there is any reduction in growth parameters. 
 screening purposes in the assay there are minimum two spheroid sets, one the 
drug/sample additions. Here the screening mode can be split into two-levels: 
i) On a basic level or 24 hour treatment. One set with only the growth
experiment) and another set with growth factor and the drug/ sample together. 
The second set of spheroids was compared with the control to analyze the 
change in spheroid pattern. 
On the second level or the 36 hour treatment, the spheroids were treated with 
stimulators alone for the first 20-24 hr period. Once th
drug/sample treatments were added along with stimulators. This was to validate 
if the drug/sample can be effective on already existing vessel formations 
(representative of in vivo situation) 
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compared to the treatment with introducing a drug along with high glucose, which 
rescues the spheroid and causes tube formation. 
As mentioned in the first chapter, different levels of angiogenesis in vivo leads to 
varied responses of the blood vessels. The tube formation is responsible in growth and 
development, in excess angiogenesis causing abnormal formation of vessels leading to 
tumors and also in insufficient angiogenesis. All the cases of angiogenesis are thus 
studied in this assay and prove its versatility thereby making it multi-functional. 
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CHAPTER V ASSAY APPLICATION 
5.1. Plants library  
The production of this assay was used to screen plant extracts which helps identify plants 
with inhibitory, stimulatory and cytotoxic effects. Natural products having pro-
angiogenic activity also demonstrate high degree of chemical diversity. 
Use of natural products to study protein function has also witnessed an increasing interest 
in identifying novel chemical agents from plants [21]. This product can be extended for 
its use to screen natural products to identify new classes of relevant non-toxic extracts to 
discover angiogenic inhibitors/drugs and cell-permeable reagents.  
Plant leaves belonging to Kentucky native plants were collected from the University of 
Kentucky-Arboretum along with a team member. An extract library of 221 plants was 
processed in the laboratory (stated in the methods section-chapter 2). The basic and 
second level screening approaches of the extracts were adapted for this application. In the 
primary screen, 44 test samples were identified to show complete and partial inhibition. 
In the second level of screening on pre-existing vessels, the spheroid assay was treated 
with growth factor for stimulating sprouts and after a 24 hour period, they were treated 
with the sample concentration. The potent samples were considered to cause collapse of 
the pre-grown vessel sprouts.  
The plants identified as positives (showing inhibition) from the two-level screening are 
considered for further analysis depending on what is already known of them and their 
relevance. From the secondary screening, 32 test samples were identified as specific 
inhibitors and 3 substances were identified as specific stimulators of VEGF induced 
sprouting and 3 were identified as being cytotoxic (causing death of the cells).This helps 
the scientists gain a very basic understanding of how multi-criterion decision making can 
be applied to help prioritize compounds as potential drug candidates. 
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Interestingly, in this blinded screening, a plant called Shrubby St. John’s wort was 
identified. It has been reported for its anti-depressent behavior. This assay was validated 
because of its ability to identify potential samples. The purpose of optimizing the assay is 
thus fulfilled. And its reproducibility can target more such compounds to reach animal-
model screens. 
               
Figure 30: Growth factor treated spheroid for 24 hour, later with the shrubby St.John’s 
wort for next 20 hours. The second image shows the inhibition of the already existed 
sprouts. 
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Figure 31: The graphical plot showing the difference in spheroid parameters after the 
treatment with plant extract over the pre-treated spheroid. There is almost a two-fold 
reduction in Total number of tubules, total length and total area of the tubules. 
5.2. Drug Screening 
One of the drug screening models is mentioned here and its assay validation is shown 
statistically. The spheroid assay was treated in high glucose of 25 mM concentration in 
the presence and absence of the drug called Benfotiamine, a potential new drug for 
diabetic treatment, at two doses of 50μM and 100μM. The researchers have reported that 
Benfotiamine halts much of the sugar accumulation [40].  The sugar accumulation in the 
experiment is shown at 25mM and there is no vessel formation (**). This model as 
mentioned earlier makes use of the drug to rescue the high glucose treated spheroids and 
foster them to new vessel formations.  
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Figure 32: Stimulatory responses of Benfotiamine treated spheroids in the presence of 
25mM glucose  
This graph shows the 25 mM Glucose (control) treated spheroids with no growth (**) and 
the significant growth when treated with the drug at respective doses. At lower dose of 
high glucose i.e at 5mM, there is significant difference in performance parameters over 
the control. The validation shows that at 100μM of Benfotiamine there is increase in total 
number, total length and total area of the tubules in comparison to 50μM of Benfotiamine 
treated spheroids.  
The above mentioned applications, validates the use of the assay for representing 
angiogenic (Benfotiamine) and anti-angiogenic (Shrubby St.John’s wort) activities of the 
drug/ samples screened. 
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CHAPTER VI CONCLUSION & FUTURE SCOPE 
As very little is known of the cellular processes and molecular controls of sprout 
formation, much investigation is going into developing assays which can give predictable 
assessment about cell regulation under different drug and no drug conditions.  
Optimized cell culture processing is one of the most important determinants of obtaining 
consistent data with cell-based assays, while at the same time the most labor intensive. 
Traditional methods used bigger format (24 or 12 well) plates for screening at a random 
pace. The smaller wells in the 96-well plate format enable around five-fold less sample to 
be used, which in itself is a significant cost reduction to the laboratory.  
The purpose of the thesis was to produce the assay, address its processing aspects, and 
the validation of various growth metrics which are the total number of tubules, average 
length of tubules and the average tubule width of the spheroid structure. In this thesis 
work, the assay was processed to an optimal stage. The product validation was performed 
and the coefficient of variation (CV) for the performance parameters was found to vary 
from 20-50 % for the spheroids under stimulation conditions using the growth factors. 
The assay was found to be robust for producing data for its analysis using the software.  
Thus the improved 3D spheroid assay, validated by the software for the first time can be 
quantified repeatedly. 
Future work on processing the assay can be done when the system will be incorporated 
with instrumentation and controls for producing the assay with minimum user 
intervention and variation. Ideas and tools for automated image capture of the spheroids 
also need to be incorporated. Like any other new manufactured product that is prototyped 
by a supplier organization and approved by its customer before taking it to the production 
stage, this project after its prototype stage will address the advanced product quality 
planning (APQP) before taking a production phase.  
On the biological value addition side, further study can be performed on screening 
various drugs with capturing any inhibitory effects on the spheroid assay to further 
elaborate its robustness on a high-throughput screening level. A system for such a 
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production can be streamlined and has a good scope to represent a pull system. Thus this 
can be extended to creating a library of data consisting of the behavior of spheroid under 
various drug effects.  
On the software analysis side, in addition to direct extraction of growth parameters 
described in the chapter four, the sprouting tubules are analyzed using a parsing method. 
In this method, a tubule growing from the spheroid is completely characterized by a 
sequence of letters from A through F. This sorting can be used to search a database of 
previously analyzed assay images to identify specific growth patterns. The measurement 
of the growth metrics is translated to total number of sequences, average number of 
letters in each sequence, and the maximum number of letters forming a sequence. This 
side of research on the software development allows building a database of assay 
sequences which allows applying statistical interference to identify specific relationships 
between assay tubule growth and the experimental conditions under which the assay was 
exposed [28]. 
Further, to develop a robust HTS assay according to the modules mentioned earlier, we 
also need to consider the biological parameters which need to be optimized for the overall 
success. Ways to reduce the background sprouting to reduce noise, by adding reagents in 
the collagen mixture or by increasing the size of spheroid or any biologically significant 
ideas can be investigated for implementation. 
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Figure 33: Inventory of cells 
 
 
Figure 34: Co-located material supply and equipment to the workstation 
 
 64
REFERENCES 
1. http://www.cnn.com/2006/HEALTH/03/15/drug.development.ap/index.html  
2. NIH Roadmap for Medical Research-Molecular Libraries and Imaging- 
http://nihroadmap.nih.gov/molecularlibraries/index.asp 
3. Wikipedia - http://en.wikipedia.org/wiki/Main_Page 
4. Burri, P.H., R. Hlushchuk, V. Djonov. 2004. Intussusceptive angiogenesis: Its 
emergence, its characteristics, and its significance. Dev. Dyn. 231:474-488. 
5. Angiogenesis protocols – J.Clifford Murray 
6. Angiogenesis in Health and Disease: Basic Mechanisms and Clinical Applications 
edited by Gabor M Rubanyi 
7. Three-dimensional cell cultures: from molecular mechanisms to clinical applications 
Wolfgang Mueller-Klieser 
 
8. Modern Methods of Drug Discovery by Gerhard Edwin Seibold, Alexander Hillisch, 
Rolf Hilgenfeld  
9. Spherogenex – Department of Vascular Biology & Angiogenesis Research tumor 
biology center Freiburg- Internet resource: http://www.spherogenex.de/ 
10. BD Biocoat Angiogenesis Systems – www.bdbiosciences.com 
11. Novel technologies and recent advances in metastasis research- Ivana Crnic And 
Gerhard Christofori Int. J. Dev. Biol. 48: 573 - 581 (2004)
 
12. Albini A, et al, J Cell Biol 105: 1867-1872, 1987. 
 
13. Taking Cell-Matrix Adhesions to the Third Dimension-Edna Cukierman, Roumen 
Pankov, Daron R. Stevens, Kenneth M. Yamada, Science 23 November 2001:Vol. 294. 
no. 5547, pp. 1708 - 1712 
 65
14. K.M.Armstrong and S. Cukierman On the Origin of Closing Flickers in Gramicidin 
Channels: A New Hypothesis Biophys. J., March 1, 2002; 82(3): 1329 - 1337. 
15. Ingber, D., 2000, "Mechanical and Chemical Determinants of Tissue Development," 
Principles of Tissue Engineering, 2nd Edition, eds., R. P. Lanza et al., Academic Press, 
Inc., San Diego, CA, pp. 101–110 
16. Chiquet, M., 1999, "Regulation of Extracellular Gene Expression by Mechanical 
Stress," Matrix biology, 18, pp. 417-426. 
17. Tensile Mechanical Properties of Three-Dimensional Type I Collagen Extracellular 
Matrices With Varied Microstructure-Blayne A. Roeder, Klod Kokini, Jennifer E. 
Sturgis, J. Paul Robinson, Sherry L. Voytik-Harbin 
18. Veis, A., and George A., 1994, "Fundamentals of Interstitial Collagen Assembly," 
Extracellular Matrix Assembly and Structure, eds., P. D. Urchenco et al., Academic 
Press, Inc., San Diego, CA, pp. 15–45. 
19. Diversity screening versus focused screening in drug discovery-Martin J.Valler and 
Darren Green 
20. Use of PROTACS as molecular probes of angiogenesis – Bargagna-Mohan P, Baek 
H, Lee H, Kim K, Mohan R. 
21. Development of Invasion and Transendothelial Migration Assays in a 96-well Format 
for Use in High-Throughput Drug Discovery.  Lakshmi Kamath, Jill S. Gregory, Marina 
J.C. Leonard, Jeanne E. Phillips and Scott Sneddon 
22. Cultrex® 3D Culture Matrix™ Rat Collagen I, Trevigen Inc. 
23. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids  
prevents apoptosis and induces differentiation. J Cell Biol 1998; 143:1341-52 
 66
24. J.M.Kelm, Nicholas E.Timmins, Catherine J.Brown, Martin Fussenegger, Lars 
K.Nielsen Method for Generation of Homogeneous Multicellular Tumor Spheroids 
applicable to a wide variety of cell types. 
25. A multicellular spheroid-based drug sensitivity test by scanning electrochemical 
microscopy Yu-Suke Torisawa, Airi Takagi, Hitoshi Shiku, Tomoyuki Yasukawa And 
Tomokazu Mats 
26. “Text on Validation of Analytical Procedures (Q2A),” the International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use Web site (Geneva: 1994 [accessed 23 November 2004]); Internet source: 
www.ich.org/MediaServer.jser?@_ID=417&@_MODE=GLB.  
27. “Validation of Analytical Procedures: Methodology (Q2B),” the International 
Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use Web site (Geneva: 1996 [accessed 23 November 2004]);  
Internet source: www.ich.org/MediaServer.jser?@_ID=418&@_MODE=GLB. 
28. Research project grant proposal document –PI Royce Mohan (2005). 
29. http://www.british-biocell.co.uk/level2.htm
30. Methods and Tools for Process Validation Wayne A Taylor- Internet source 
http://www.variation.com/techlib/val-1.html 
31. Statistical practices in assay development and validation-Implementing proper 
statistical methods ensures the development of safe and effective assays Anastasia N. 
Derzko  
32. Basic Production System concepts – University of Kentucky 2005 
 
33. Process Quality Control-Troubleshooting and interpretation of Data – Ellis R.Ott 
 
34. Quality and Statistics: Total Quality Management – Milton J. Kowalewski, Jr. 
 67
35. Responding to Variation: Common Causes- Skymark Corporation 
http://www.skymark.com/resources/responding_to_common_cause_variation.asp  
36. GHTF Study Group 3 - Quality Management Systems Process Validation Guidance– 
January 2004 
 
37. Spheroid preparation from hanging drops: characterization of a model of brain 
tumour invasion Danny D. Duca, Tamra Werbowetski and Rolando F. Del Maestro 
 
38. NIH guidance manual- Transfer of Validated assays 
http://www.ncgc.nih.gov/guidance/section2.html#variability-assessment 
39. Withaferin A is a potent inhibitor of angiogenesis- Mohan R, Hammers HJ, 
Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, Zhang L, Hanson AD, Conner BP, 
Rougas J, Pribluda VS.  
40. Internet source: http://www.antiaging-systems.com/a2z/benfotiamine.htm 
  
 
 
 
 
 
 68
VITA 
 
The author was born in Hyderabad, Andhra Pradesh, India on July 25th 1983. She 
graduated from high school in 2000 to later earn her Bachelors degree in Mechanical 
Engineering. During the year 2003, she interned as process engineer at Hindustan 
Aeronautics Limited, Hyderabad, India. She came to the United States in 2004 to pursue 
her Masters in Manufacturing Systems Engineering. With encountering a unique project 
in 2005, she took up to shape this biological manufacturing project which earned her a 
manuscript. Her research efforts will account to submissions of two other manuscripts in 
the field of drug screening.  
 
 
 69
